Study of an injection for relapsed or refractory myeloma
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new injected drug for people with multiple myeloma that has returned or stopped responding to at least 3 prior treatments. The goal is to see if the drug is safe and works against the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have multiple myeloma that can be measured by tests.
- You have had at least 3 prior treatments for myeloma and your cancer has come back or not responded.
- You are able to use birth control if needed.
- You have not had certain other plasma cell disorders or active brain involvement.
- Your organs and bone marrow are working well enough.
- You have not had certain immune cell therapies within the last 90 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational injection called WGb-0302 for people with multiple myeloma that has come back or not responded to standard treatments. The goal is to see if it is safe and helpful, possibly by targeting a protein on the cancer cells called BCMA.
This trial tests a new experimental drug called CM336 for people with multiple myeloma that has come back or stopped responding to standard treatments. The drug may work by helping your immune system attack and destroy myeloma cells. If you join, you will receive the study treatment and be closely monitored to see how well it works and how safe it is.
This study tests an experimental drug called RN9101 for people with multiple myeloma that has returned or stopped responding to other treatments. The drug targets a protein called BCMA found on myeloma cells, and the goal is to see if it is safe and can help control the disease.
This trial tests an experimental drug for multiple myeloma that has come back or not responded to at least three previous treatments. It aims to see if the drug can help people whose cancer has progressed despite prior therapies including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody.
This trial tests a new injectable treatment for people with multiple myeloma that has come back or not responded to previous therapies. It aims to see if the drug is safe and effective.
This study tests an experimental drug called LBL-034 for people whose multiple myeloma has come back or stopped responding to treatment. The goal is to see if it is safe and effective.
Hear when a new Plasma Cell Myeloma Refractory trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.